(Recording) ECHO 1: Perception is More Important than Reality – Aligning Beliefs of Patients and Providers to Promote Actions in Effective Weight Management

Each ECHO will have a live and on-demand component; those who participate in the live ECHO may receive credit from the live event but are not eligible to receive credit for the on-demand webinar. For those who registered for the live event but did not attend, your enrollment has been shifted to this course.

Endocrine Society is pleased to participate in Project ECHO: Approaches to Long-Term Weight Loss and Obesity Care webinar series. The first ECHO, Perception is More Important than Reality – Aligning Beliefs of Patients and Providers to Promote Actions in Effective Weight Management, focused on myths, common misconceptions, and fads in obesity and obesity treatment.The live ECHO took place on July 28, 2020; this course contains the recording from the live event, and is eligible for CME from 8/3/2020-12/31/2022. 

Please note that to participate in this ECHO, you must complete registration for the Project ECHO program.

About this ECHO:

Myths, common misconceptions, and fad treatments abound in obesity and are barriers to patient access to medical weight management. While the majorities of both patients (65%) and providers (80%) agree that obesity is a disease, opinions on who should be responsible for management, and methods to manage weight loss, differ greatly. Most persons with obesity (82%) endorse that weight management is “completely my responsibility.”  Historically, persons with obesity seek information and treatment for weight loss not from their health care provider, but from the internet, popular books, talk show hosts and the supplement aisle. Looking elsewhere could be considered a failure of the medical establishment to address their needs, whether it is in helping them to understand their disease process or in guiding them on all available weight loss options. When it comes to helping patients with weight management as a pathway to better health outcomes, how can the committed health care provider engage patients in this process? This webinar reviews the ACTION (Awareness, Care, and Treatment in Obesity Management) Study1, a survey that examined obesity-related perceptions, attitudes, and behaviors among 3008 people with obesity, 606 health care providers, and 153 employer representatives. ACTION identifies discrepancies in perceptions and attitudes between the three sampled groups. This webinar uses those inconsistencies in perception between providers and persons with obesity to identify barriers to effective patient engagement and obesity management in the health care setting. Using case-based discussions, the webinar provides tools, resources, and scripts to promote patient perception of weight management as an essential component of chronic disease prevention and management.


1. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective Obesity Care: Results from the national ACTION study. Obesity (2018) 26, 61-69. doi:10.1002/oby.22054

Target Audience

This program will be of substantial interest to endocrinologists and fellows caring for individuals with, or at risk for developing, obesity and associated diseases. Additionally, this program may be of interest to primary care professionals and advance practice professionals who treat patients with obesity.

Learning Objectives

At the end of the webinar, participants will be able to:

1.    Discuss common perceptions among persons with obesity and their health care provider on the following topics: obesity as a disease, diagnosis of obesity, responsibility for weight management, patient motivation and perceived efficacy of weight loss treatments;
2.    Describe techniques for opening discussions about obesity and weight management and for motivational interviewing; and
3.    Discuss patient education tools and scripts for responding to common myths and erroneous beliefs about body weight regulation, drivers of weight gain and evidence-based weight management techniques. 

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
Course expires: 


Donna H. Ryan, MD
Pennington Biomedical Research Center


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported the following relevant financial relationships: Donna H. Ryan, MD - Self: Alyvent, Bausch Health, Boeringer Ingelheim, Epitomee, Janssen, Novo Nordisk, real appeal (United Health), ReDesign Health, and Sanofi - Consulting Fee. Self: Novo Nordisk, Bausch Health - Speakers Bureau. Self: Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake - Ownership Interest. Self: SELECT Steering Committee (Novo Nordisk) - Research.

Disclosure information for guest speakers is included in their individual recorded presentations.

The following peer reviewers reported no relevant financial relationships: Beret A. Casey, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. 

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit may be claimed from 8/5/2020-12/31/2022.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation